Tech Company Financing Transactions

Stalicla Funding Round

On 1/16/2024, Stalicla raised $17.4 million in Series B financing from SPRIM Global Investments and private investors.

Transaction Overview

Company Name
Announced On
1/16/2024
Transaction Type
Venture Equity
Amount
$17,400,000
Round
Series B
Investors

SPRIM Global Investments (Lead Investor)

Proceeds Purpose
The company intends to use the funds for (i) preparation of Stalicla's pioneering precision Autism Spectrum Disorder (ASD) Phase 2 trial -- STP1; (ii) the establishment of its STP7 mGluR5 Negative Allosteric Modulator (mGluR5 NAM) platform, including the launch a Phase III study in Substance Use Disorders (SUDs) slated for 2025, fully supported by the NIH /National Institute on Drug Abuse; (iii) the ramp up of its ongoing biosampling/ patient identification trial STA-B-001 currently enrolling in sites in the USA, Spain and Australia.

Company Information

Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Avenue de Secheron 15 Campus Biotech Innovation Park
Genève, 1202
Switzerland
Email Address
Overview
STALICLA is a clinical-stage biopharmaceutical company with a team of domain experts, drug developers, clinicians, data scientists and computational biologists working to create NDD precision medicine solutions. 24 employees coming from world leading academic and large pharmaceutical centers (UCLA Geschwind Lab, BCN Super Computing Center, Max Planck Institute, ...) and large Pharmaceutical (Novartis, Roche, Takeda, Lundbeck, ...).
Profile
Stalicla LinkedIn Company Profile
Social Media
Stalicla Company Twitter Account
Company News
Stalicla News
Facebook
Stalicla on Facebook
YouTube
Stalicla on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Lynn Durham
  Lynn Durham LinkedIn Profile  Lynn Durham Twitter Account  Lynn Durham News  Lynn Durham on Facebook
Chief Financial Officer
Laurent Forestier
  Laurent Forestier LinkedIn Profile  Laurent Forestier Twitter Account  Laurent Forestier News  Laurent Forestier on Facebook
Chief Medical Officer
Atul Mahableshwarkar
  Atul Mahableshwarkar LinkedIn Profile  Atul Mahableshwarkar Twitter Account  Atul Mahableshwarkar News  Atul Mahableshwarkar on Facebook
Chief Operating Officer
Eric Painbeni
  Eric Painbeni LinkedIn Profile  Eric Painbeni Twitter Account  Eric Painbeni News  Eric Painbeni on Facebook
Chief Technical Officer
Emre Guney
  Emre Guney LinkedIn Profile  Emre Guney Twitter Account  Emre Guney News  Emre Guney on Facebook
VP - Client Services
Jean-Marc Hyvelin
  Jean-Marc Hyvelin LinkedIn Profile  Jean-Marc Hyvelin Twitter Account  Jean-Marc Hyvelin News  Jean-Marc Hyvelin on Facebook


 

 

Browse more venture capital transactions:

Prev: 1/16/2024: Zeal IO venture capital transaction
Next: 1/16/2024: BeWater venture capital transaction

 

Share this article

 


About Database of VC Transactions

We do our best to record every notable VC transaction. All VC database entries on this site are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.

 


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary